Skip to main content
SUPN
NASDAQ Life Sciences

Supernus Q2 Revenue Jumps 32%, Raises Full-Year Guidance Amid Merger Announcement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$49
Mkt Cap
$2.59B
52W Low
$32.83
52W High
$59.68
52W Position info
49% above low
Off High info
18% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SUPN sits 49% above its 52-week low of $32.83.

Summary

Supernus reported Q2 2026 revenue of $219.1M (+32% YoY) and raised full-year guidance, but a non-cash impairment charge led to a GAAP loss. The results coincide with the announcement of a merger with Indivior.


Key Events · Earnings and Guidance · SUPN

  • Q2 Revenue Surges 32%

    Total revenues reached $219.1 million, up from $165.5 million a year ago, driven by 52% growth in combined sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO.

  • Full-Year Guidance Raised

    Revenue guidance lifted to $860M-$890M (from $840M-$870M) and adjusted operating earnings to $150M-$180M (from $140M-$170M), reflecting confidence in growth products.

  • GAAP Loss on Impairment

    A $54.9 million non-cash intangible asset impairment for APOKYN drove a GAAP operating loss of $58.0 million and a net loss of $58.4 million ($1.01 per share).

  • ONAPGO Regulatory Progress

    Submission for a second ONAPGO supplier remains on track for Q3 2026, with potential FDA approval by mid-2027, supporting supply chain resilience.


Analysis · SUPN · Life Sciences

Supernus delivered a strong Q2 with total revenues up 32% to $219.1 million, driven by 52% growth in its four key products. The company raised its full-year 2026 revenue and adjusted operating earnings guidance, signaling confidence in sustained momentum. However, a $54.9 million non-cash impairment on APOKYN pushed GAAP results to a loss, and the guidance range for GAAP operating loss widened. The results land on the same day as the announcement of a merger of equals with Indivior, adding strategic complexity. Investors will weigh the strong commercial execution against the dilution and integration risks of the pending all-stock merger.

At the time of this filing, SUPN was trading at $49.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $32.83 to $59.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SUPN - Latest Insights

SUPN
Aug 03, 2026, 6:43 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $47.51
Real-time Price: $50.60 info
Change: +$3.09 (+7%) info
Market Cap: $2.59B info
SUPN
Aug 03, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $44.21
Real-time Price: $50.60 info
Change: +$6.39 (+14%) info
Market Cap: $2.59B info
SUPN
Jun 18, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.38
Real-time Price: $50.60 info
Change: +$6.22 (+14%) info
Market Cap: $2.59B info
SUPN
May 20, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.69
Real-time Price: $50.60 info
Change: +$1.91 (+4%) info
Market Cap: $2.59B info
SUPN
May 05, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $51.50
Real-time Price: $50.60 info
Change: -$0.900 (-2%) info
Market Cap: $2.59B info